Current topics in behavioral neurosciences
January 1, 2022
Fernanda Palhano-Fontes, Bruno Lobão Soares, Nicole Leite Galvão-Coelho et al.
25 citations
Ayahuasca, a psychedelic brew containing DMT and MAOIs, shows rapid antidepressant effects in clinical trials. Evidence from open and placebo-controlled studies indicates significant improvement starting as early as one day after administration. This article reviews the history, pharmacology, clinical trials, and behavioral markers of ayahuasca's antidepressant properties.
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
July 28, 2017
Robson Savoldi, Daniel Polari, Jaquelinne Pinheiro Da Silva et al.
Ayahuasca, a traditional Amazonian infusion made from Banisteriopsis caapi stem and Psychotria viridis leaves, contains N,N-dimethyltryptamine (DMT) and monoamine oxidase inhibitors. In adult zebrafish exposed to five concentrations (0, 0.1, 0.5, 1, and 3 ml/L, with 14 fish per group), swimming speed and distance traveled decreased with higher concentrations, while freezing and bottom dwelling increased at 1 and 3 ml/L. At 0.1 ml/L, bottom dwelling declined, suggesting reduced anxiety-like behavior. Low doses did not affect locomotion and appeared anxiolytic, whereas higher doses produced anxiogenic effects. Temporal behavioral analysis in zebrafish offers a sensitive method for studying ayahuasca-induced brain changes.